Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutations in advanced colorectal cancer: the dark side of the moon.

Oncology - 1 Jan 2014

Pietrantonio Filippo, Biondani Pamela, Perrone Federica, Di Bartolomeo Maria, Pacifici Monica, Milione Massimo, Melotti Flavia, Maggi Claudia, Montemurro Gabriella, Bossi Ilaria, Mariani Luigi, de Braud Filippo

Abstract excerpt

BACKGROUND: Evidence for TP53 mutations as biomarker in colorectal cancer (CRC) is conflicting. METHODS: We assessed TP53 mutations in 51 patients with advanced CRC enrolled into a phase II, randomised trial of first-line tegafur-uracil (UFT)/leucovorin (LV) plus irinotecan (n = 23) versus UFT/LV plus oxaliplatin (n = 28). RESULTS: Non-functional TP53 mutations were found in 35% of patients. The response rate was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Proportional Hazards Models

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 24924261
DOI: 10.1159/000360088

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations in advanced colorectal cancer: the dark side of the moon.PMID 24924261Read ↗

Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.Semantic proximity Read ↗

The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.Semantic proximity Read ↗

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.Semantic proximity Read ↗

Studying the Impact of Tp53 Mutations on Colorectal Cancer Pathogenesis and Therapeutic Response in a Tunisian PopulationSemantic proximity Read ↗

Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.Semantic proximity Read ↗

The prognostic role of p53 mutations in metastatic colorectal cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.Semantic proximity Read ↗

Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.Semantic proximity Read ↗

Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.Semantic proximity Read ↗

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).Semantic proximity Read ↗

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.Semantic proximity Read ↗

P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.